

3<sup>rd</sup> EDITION

**VAXON**

# CANCER VACCINES 2026

Actual Landscape, Rational  
Combinations, and New Frontiers in  
**IMMUNO-ONCOLOGY**

**CME course**

**Naples**  
**October 5<sup>th</sup> | 2026**

**Royal Continental Hotel**  
**via Partenope, 38**

Provider ECM

  
**ideA-Z**  
EventsThinkers

Organizing Secretariat

 **vivenko**  
SOCIETÀ A RENDIMENTO



## PRESIDENCY

### **Paolo A. Ascierto**

*Full Professor, University of Naples Federico II; Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy*

### **Bernard A. Fox**

*Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US*

## RATIONAL

*After decades of research and clinical trials, vaccines are beginning to impact patient outcomes and pushing the boundaries of research in the field of immuno-oncology. While the future is bright, we still have a long way to go.*

*This year, the third edition of the event will be an international meeting for experts to share and discuss the latest findings and future perspectives on cancer vaccines and immunotherapy*

# SCIENTIFIC PROGRAM

8:45am Registration \*\*

9:00am Welcome and Introduction of the Meeting  
**Paolo A. Ascierto**

9:05am Framing Remarks: Cancer Vaccines 2026, why now?  
**Bernard A. Fox**

- What has changed since earlier vaccine failures?
- Personalized vs shared antigen strategies
- mRNA/LNP, neoantigen prediction, immune monitoring, and combination immunotherapy
- Defining success: tumor regression, recurrence prevention, durability, or cure

9:20am Dark Proteome – The Undiscovered Targets for Cancer Immunotherapy  
**Reuven Agami**

## SESSION I

**Dark Proteome Cancer Vaccines – Where are they going?**

**Chairpersons: Paolo A. Ascierto, Bernard A. Fox**

09:45am Expanding the landscape of tumor antigens in breast cancer through Immunopeptidomics  
**Eralda Kina**  
Q&A

10:05am Microproteins as cancer vaccine targets in liver cancer and beyond  
**Júlia Perera Bel**  
Q&A

10:25am Pancreatic Cancer  
**Rishi Surana**  
Q&A

\*Invited Speaker

\*\*Not included in the CME accredited

# SCIENTIFIC PROGRAM

## 10:45am **Panel Discussion**

- Shared antigen off-the-shelf vaccine approaches
- Lessons from emerging FIH trials
- What endpoints matter: immune response, pathologic response, recurrence-free survival, overall survival

11:00am Coffee Break\*\*

## SESSION II

### The Clinical Landscape – Shared Canonical and Neoantigens

**Chairpersons: Paolo A. Ascierto, Bernard A. Fox**

11:15am Minimal residual disease vs metastatic disease: focus on Melanoma  
**Paolo A. Ascierto**  
Q&A

11:35am Fixed vaccines vs personalized vaccines  
**Nina Bhardwaj**  
Q&A

11:55am Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)  
**Craig L Slingluff Jr\***  
Q&A

12:15pm Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1  
**Paolo A. Ascierto**  
Q&A

\*Invited Speaker

\*\*Not included in the CME accredited

# SCIENTIFIC PROGRAM

## 12:35pm **Panel Discussion**

Focus: Which antigens should vaccines target? What do the trials say?

- Private neoantigens vs recurrent driver mutations
- Tumor-associated antigens, cancer-testis antigens, viral antigens
- Antigen clonality, heterogeneity, loss, and immune escape
- Antigen spreading as a marker of productive immunity
- Implications for lung, prostate, and melanoma vaccine design

12:50am Lunch\*\*

## SESSION III

### **What Should Be Added to Cancer Vaccines and When? Combination immunotherapy, schedule, sequencing, and immune context**

**Chairpersons: Paolo A. Ascierto, Bernard A. Fox**

01:50pm PD-1 biology, memory T-cell formation, costimulation, and myeloid biology  
**Rom Leidner**

02:10pm Impact of LNP delivered mRNA on the response to anti-PD-1  
**Christiano Marconi**

02:30pm AI in trial monitoring and immune-response assessment  
**Carlo Bifulco**

02:50pm **CME Test\*\***

\*Invited Speaker

\*\*Not included in the CME accredited

# SCIENTIFIC PROGRAM

## SESSION IV: NO CME SESSION

### Trials and Clinical Research\* \*

**Chairpersons: Paolo A. Ascierto, Bernard A. Fox**

**03:00pm** Nous-209 off-the-shelf Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers  
**Morena D'Alise**  
**Q&A**

**3:20pm** Multi-omics-guided design of shared vaccines against HERV antigens in cancer  
**Daniela Kleine-Kohlbrecher**  
**Q&A**

**3:40pm** Closing Remarks  
**Paolo A. Ascierto, Bernard A. Fox**

\*Invited Speaker

\* \*Not included in the CME accredited

# FACULTY

**REUVEN AGAMI**, Head of Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Full Professor Department of Molecular Genetics, Erasmus MC, Rotterdam, The Netherlands

**PAOLO A. ASCIERTO**, Full Professor, University of Naples Federico II; Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

**NINA BHARDWAJ**, Director of Immunotherapy, Medical Director of the Vaccine and Cell Therapy Laboratory, Ward-Coleman Chair in Cancer Research, Professor of Medicine (Hematology and Medical Oncology) and Urology, Mount Sinai Tisch Cancer Center, New York, US

**CARLO BIFULCO**, Medical Director of Cancer Genomics and Precision Oncology, Providence Cancer Institute, Portland, Oregon, US

**MORENA D'ALISE**, VP of Immunology, Nouscom Srl, Rome, Italy

**BERNARD A. FOX**, Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, US

**ROM LEIDNER**, Director Immune Cell Experimental Therapy; Co-Director, Head and Neck Cancer Program Member, Earle A. Chiles Research Institute, Providence Cancer Institute Portland, Oregon, US

**ERALDA KINA**, Medical Oncologist and Researcher, Charles-Lemoyne Hospital; Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada

**DANIELA KLEINE-KOHLBRECHER**, Director, Immuno-oncology, Evaxion Biontech, Hørsholm, Denmark

# FACULTY

**CHRISTIANO MARCONI**, Researcher, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, US

**JÚLIA PERERA BEL**, Head of Bioinformatics Unit, Hospital del Mar Research Institute; Associate lecturer in bioinformatics, Pompeu Fabra University, Barcelona, Spain

**CRAIG L. SLINGLUFF**, Professor of Surgery, Division of Surgical Oncology, Breast and Melanoma Surgery; Director, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, US

**RISHI SURANA**, Medical Oncologist, Dana-Farber Cancer Institute; Instructor in Medicine, Harvard Medical School, Boston, MA, US

# CME

ID CME 335- 493690 Ed. 1

4 CME credits.

Formative Technical Professional Objective “Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and gender medicine”.

50 participants (medical doctors, pharmacists SSN).

In order to receive CME credits, participants must:

1. attend at least 90% of the accredited CME sessions (attendance check: required signature at the beginning and at the end of works);
2. fill in the CME test (minimum 75% correct answers required);
3. fill in the evaluation form.

Ecm certificate will be issued to successful applicants within 90 days after the end of the conference

## REGISTRATION

Registration is free of charge for medical and clinical professionals.

For registration, please visit: [VAX ON 2026 - Vivenko](#)

For information, please send an e-mail to: [eventi@vivenko.net](mailto:eventi@vivenko.net)

## OFFICIAL LANGUAGE

The official language is English.

### **PROVIDER ECM**

**ideA-Z Project in progress S.r.l.**

Provider E.C.M. Standard n. 335

Corso Giacomo Matteotti, 48

20081 Abbiategrasso (MI)

info@idea-z.it - [www.idea-z.it](http://www.idea-z.it)



### **SEGRETERIA ORGANIZZATIVA**

**Vivenko Srl Società Benefit**

Via De Amicis 42, 20123 Milano

[www.vivenko.net](http://www.vivenko.net)

